Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 1.00 |
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984446 | 0.87 | NOTUM (0.77) | NOTUMCNR2BIRC2HTR3EHTR3B | |
| SCHEMBL26691209 | 0.84 | NOTUM (0.73) | NOTUMCNR2AMPD2BIRC2HTR3E | |
| SCHEMBL26932396 | 0.84 | NOTUM (0.73) | NOTUMCNR2AMPD2BIRC2HTR3E | |
| Quinoline SCHEMBL27975048 | 0.84 | NOTUM (0.70) | NOTUMCNR2AMPD2KDM4EALDH1A1 | |
| SCHEMBL10560315 | 0.83 | NOTUM (0.71) | NOTUMCNR2KDM4EALDH1A1 | |
| SCHEMBL27565401 | 0.81 | NOTUM (0.69) | NOTUMCNR2BIRC2HTR3EHTR3B | |
| SCHEMBL24097911 | 0.81 | NOTUM (0.68) | NOTUMAMPD2KDM4EALDH1A1 | |
| SCHEMBL17446885 | 0.81 | NOTUM (1.00) | NOTUMAMPD2KDM4EALDH1A1 | |
| SCHEMBL3459360 | 0.79 | NOTUM (0.66) | NOTUMAMPD2KDM4EALDH1A1 | |
| SCHEMBL2746952 | 0.78 | NOTUM (0.64) | NOTUMCNR2AMPD2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | claimed |
| WO-2005092853-A1 | METHOD FOR PRODUCING 5-BROMO-3,3-DIMETHYL-2,3-DIHYDRO-1H-INDOLE HYDROCHLORIDE | BAYER HEALTHCARE AG (DE) | 2005-10-06 | — | — | WO | claimed |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. | 2005-03-10 | — | — | US | claimed |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | AMGEN INC. | 2005-03-03 | — | — | US | claimed |
| US-20170066776-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9540349-B2 | Substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160016937-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014089324-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-06-12 | — | — | WO | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| US-4863945-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0271040-A2 | Pyrrolobenzimidazoles, process for their preparation, and medicaments | Roche Diagnostics GmbH (DE) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | NOTUM 1635/4885CNR2 100/4885AMPD2 404/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | NOTUM 2149/4885CNR2 363/4885AMPD2 1265/4885 |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | NQO1, NQO2, UGT1A1 | NOTUM 2394/4885CNR2 602/4885AMPD2 1797/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | NOTUM 1596/4885CNR2 42/4885AMPD2 434/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | NOTUM 2089/4885CNR2 22/4885AMPD2 453/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | NOTUM 2149/4885CNR2 363/4885AMPD2 1265/4885 |
| US-20160016937-A1 | Novel substituted pyrimidine compounds | PDE4A, PDE4B, TYMP | NOTUM 1560/4885CNR2 1602/4885AMPD2 151/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | NOTUM 2149/4885CNR2 363/4885AMPD2 1265/4885 |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | VHL, DPYD, UGT1A1 | NOTUM 2837/4885CNR2 601/4885AMPD2 1227/4885 |
| US-20170066776-A1 | Novel substituted pyrimidine compounds | PDE4A, PDE4B, TYMP | NOTUM 1560/4885CNR2 1602/4885AMPD2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.